U.S. FDA Approves Biosimilar Amjevita for Multiple Inflammatory Diseases

U.S. FDA Approves Biosimilar Amjevita for Multiple Inflammatory Diseases
The Division of Drug Information at the U.S. Food and Drug Administration (FDA) has announced its  approval of Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for the treatment of multiple inflammatory diseases, including inflammatory bowel diseases (IBDs). The FDA approved Amjevita for the treatment of a number of inflammatory diseases, including moderate-to-severe active Crohn’s disease and

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *